samedan logo
 
 
spacer
home > pmps > summer 2019 > accuracy in patch pump therapy
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Accuracy in Patch Pump Therapy

Patch pump therapy is a convenient method of drug administration. The devices can be worn directly on the body, no tubing has to be attached, and the cannula or needle is inserted automatically. They are often equipped with programmable delivery patterns, which allow high flexibility and a rational adjustment to the patientís needs. In turn, the patch pumps must fulfil the highest criteria in dosage accuracy and safety. The fluidic path through the whole device, including body resistance at the injection site combined with the physical properties of the drug, define the pressure loss that the pump needs to overcome. Since smaller needles are more comfortable and, therefore, preferred, they often represent the bottleneck of the system.

Viscosity Range of Suitable Medication

Many common drugs for patch pump therapy are aqueous solutions in the range of 1cP to 30cP. Fluids with higher agent concentration or larger molecules may reach up to 50cP or even higher. This often requires large needle diameters or significantly lower flow rates.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Michael Girschweiler has worked at Sensile Medical since 2017. Michael is Technical Project Leader in the field of micropump development and an expert in the companyís pump core technology. He has a Bachelorís degree in Mechanical Engineering and worked as Research Assistant at the Institute of Thermal and Fluid Engineering at the University of Northwestern Switzerland, mainly in FEM and CFD simulations of thermomechanical projects.
spacer
Michael Girschweiler
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group

Cambridge, UK, 28 October 2021: Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million (circa £30 million) investment round. The round was led by Sofinnova Partners (Paris, France) and Redmile Group (San Francisco, USA) co-investing on equal terms.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement